Tandem Diabetes Takes Aim at Medtronic's Artificial Pancreas - Nasdaq


Nasdaq

Tandem Diabetes Takes Aim at Medtronic's Artificial Pancreas
Nasdaq
Insulin pump maker Tandem Diabetes Care (NASDAQ: TNDM) has secured an FDA OK that puts it on track to challenge Medtronic (NYSE: MDT) for the lead in the emerging market for closed-loop insulin systems. Is Tandem Diabetes stock a buy?

and more »


from diabetes - Google News